Accessibility Menu
Bio-Path logo

Bio-Path(OTC) BPTH

Current Price$0.04
Market Cap$2.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 YearN/A
1 Year-74%
1 Month+14%
Bio-Path last closing stock price
MetricPriceDate
Last closeUSD 0.042026-07-24
Bio-Path stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.26%USD 0.042026-07-17
1 month+14.29%USD 0.042026-06-24
3 month-28.38%USD 0.062026-04-24
Year to date-33.33%USD 0.062025-12-31
1 year-74.19%USD 0.162025-07-24
Since inception-100%USD 3,000.002008-02-15

Bio-Path Financials at a Glance

Market Cap

$2.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$6.09M

EPS (TTM)

-$0.72

P/E Ratio

-0.06

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.04

Volume

1,603

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.01 - $0.15

Estimated Earnings Date

Aug 18, 2026

BPTH News

3 Humongous Health-Care Stocks This Week

Keith SpeightsApr 13, 2014

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bio-Path

Bio-Path develops drugs for cancer and metabolic diseases. Its treatments aim to help patients with hard-to-treat conditions. The company uses a special technology to deliver these drugs more effectively.

Lab Bench to Bedside: What Bio-Path Sells

  • Prexigebersen (BP1001): Drug in clinical trials for blood cancers like acute myeloid leukemia; no revenue generated.
  • Liposomal Bcl-2 (BP1002): Drug candidate for relapsed lymphoma and leukemia; no commercial sales.
  • Liposomal STAT3 (BP1003): Early-stage drug for pancreatic and lung cancers; not yet approved or sold.
  • Prexigebersen-A (BP1001-A): Modified drug for solid tumors and metabolic diseases; in early testing, no revenue.
  • DNAbilize platform: Technology for delivering drugs to target disease genes; supports all pipeline products.

Growth Spurts and Stumbles: Bio-Path’s Expansion Story

  • Expanded pipeline to include obesity and Type 2 diabetes in 2024.
  • Raised capital through direct offerings and private placements in 2024 and 2025.
  • Delisted from Nasdaq in February 2025; now trades over-the-counter.
  • Paused operations and furloughed most employees in June 2025 to conserve cash.

Why Bio-Path Is a Bit Different

Bio-Path’s DNAbilize technology aims to deliver drugs directly to disease-causing genes, potentially reducing side effects. The company focuses on diseases with few treatment options, using a targeted approach. Its small size allows for quick shifts in research focus, but also brings funding challenges.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Net loss was $-5 million in Q2 2025, 7.5% higher (more negative) than Q2 2023.
  • Cash flow from operations improved 91.2% to $-283,000 in Q2 2025.
  • Cash balance was $0 as of June 30, 2025, raising going concern risks.

Bottom Line

Bio-Path remains a research-focused biotech with no commercial products and ongoing funding challenges. Its future depends on securing capital and advancing its drug pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Vikram Grover, CFA

Website

www.biopathholdings.com

Headquarters

Bellaire, TX 77401, US

BPTH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

76.46%

Return on Capital

N/A

Return on Assets

-899.85%

Earnings Yield

-16.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.30M

Volume

1.60K

Avg. Volume

31.83K

Financials (TTM)

Gross Profit

-$75.00K

Operating Income

-$5.39M

EBITDA

-$5.67M

Operating Cash Flow

-$321.00K

Capital Expenditure

$0.00

Free Cash Flow

-$321.00K

Cash & ST Invst.

$12.00K

Total Debt

$511.00K

Bio-Path Performance Analysis

Bio-Path annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Bio-Path sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Bio-Path annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -38.1222.8%
20232023-12-31USD -33.64-11.8%
20242024-12-31USD -4.12-87.7%
20252025-12-31USD -1.10-73.4%
Bio-Path sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-37.5%
Q32025-09-3080.0%
Q42025-12-3175.5%
Q12026-03-31-7.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$11.00K

+65.6%

Gross Margin

0.00%

N/A

Market Cap

$2.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.01M

N/A

Employees

1

N/A

Net Income

-$270.00K

+90.5%

EBITDA

-$286.00K

+89.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$12.00K

-90.2%

Total Debt

$511.00K

+62.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$511.00K

+62.2%

Return on Assets

-9.00%

N/A

Return on Invested Capital

63.58%

N/A

Free Cash Flow

-$38.00K

+97.1%

Operating Cash Flow

-$38.00K

+97.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ORGSOrgenesis Inc.
$0.40+0.00%
ELLXFElixinol Wellness Limited
$0.01-1.89%
EMMAEmmaus Life Sciences, Inc.
$0.01+0.00%
SQZBSQZ Biotechnologies Company
$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Questions About BPTH

What is the current price of Bio-Path?

Bio-Path is trading at $0.04 per share.

What is the 52-week range for Bio-Path?

Over the past 52 weeks, Bio-Path has traded between $0.01 and $0.15.

How much debt does Bio-Path have?

As of the most recent reporting period, Bio-Path reported total debt of $511.00K.

How much cash does Bio-Path have on hand?

Bio-Path reported $12.00K in cash and cash equivalents in its most recent financial results.

What is Bio-Path’s dividend yield?

Bio-Path does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services